Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

7

Revenue 2017

GlaxoSmithKline

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of GlaxoSmithKline's 2013 sales performance.

GlaxoSmithKline

GSK gets maintenance indication for Trelegy

GSK gets maintenance indication for Trelegy

GlaxoSmithKline is celebrating an expanded US approval for its triple respiratory drug Trelegy, which it has long held up as one of its most important new product launches.

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more GlaxoSmithKline presents its results from the first quarter later today, with updates on key launches, the new $13bn buy-out of Novartis from the consumer health joint venture, and the unveiling

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn Just this month, for example, GlaxoSmithKline divested its rare disease portfolio to start-up Orchard Therapeutics, after buying Novartis out of a consumer health joint venture in March, and Shire has

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics